The incidence of abdominal aortic aneurysms (AAA) in people aged >60 years is approximately 5% in men and 1% in women. The results of four currently available randomized controlled studies (RCTs) suggest that: the probability of rupture of a small AAA (<55 mm) is approximately 0.5-1%/year, with an overall patient mortality rate of 3-6%, of which approximately 40% is due to cardiovascular disease not directly related to the AAA; surgical intervention in patients with AAAs of 40-54 mm does not provide a survival advantage; >55 mm or symptomatic AAAs are indicative of surgical intervention; and >5 mm or symptomatic AAAs are indicative of surgical intervention. 55 mm or symptomatic AAA is an indication for surgical intervention.Surgical interventions for AAA include open surgery and endovascular repair. However, both have certain limitations. Open surgery has a perioperative mortality rate of 5%, in addition to other serious complications such as prolonged recovery time. Although endoluminal repair has a relatively low perioperative mortality and complication rate and has the advantage of rapid recovery, durability is a serious concern and requires long-term imaging and clinical follow-up. Moreover, most AAAs are initially detected with aneurysms <5.5 cm.Therefore, rupture of AAA as well as the use of surgical treatment can be avoided if conservative treatment with the application of pharmacological therapy can limit the growth of the AAA. Several therapeutic options have been proposed based on the results of studies of experimental animal models of abdominal aortic aneurysms, clinical trials, and analyses of trial records related to abdominal aortic aneurysms. Pharmacologic treatments include hormones, vitamins, statins, doxycycline, vitamin E, cyclooxygenase-2 inhibitors, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers.